Evidence map›Paper›PMID 39766267›Full record

ArticleBiomolecules2024

The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.

Jood Hashem, Farah Alsukhni, Hassan Abushukair, Mahmoud Ayesh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jood HashemDepartment of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan.
Farah AlsukhniDepartment of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan.
Hassan AbushukairFaculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.ORCID 0000-0002-0068-5201
Mahmoud AyeshFaculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.ORCID 0000-0001-9963-6663

Funding

Jordan University of Science and Technology 20190255
6 · The paper itself

Abstract

The efficacy of statins as anti-cancer drugs has been demonstrated in several malignancies but has been poorly investigated in hematological malignancies (HM). By studying its effect on oncogenic miRNAs, we investigated the effect of statin therapy on HM patients. The data were used to identify enriched pathways that were altered due to statin treatment. The main aim of this study was to identify significantly differentially expressed miRNAs and involved regulatory pathways post-atorvastatin treatment in HM patients. A panel of 95 plasma circulating miRNAs involved in tumorigenesis, apoptosis, and differentiation were relatively quantified using qPCR for blood samples obtained from 12 HM patients, 4 with Chronic Myeloid Leukemia (CML), 4 with Non-Hodgkin Lymphoma (NHL), and 4 with Essential Thrombocythemia. Pre- and post-administration of a 6-week atorvastatin course miRNA expression levels were measured. Significantly differentially expressed miRNAs were those with a fold change >2 or <0.5 using the Livak method with a two-sided

Indexed as

AtorvastatinHematologic NeoplasmsMicroRNAsAdultAgedFemaleGene Expression Regulation, NeoplasticHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedSignal TransductionAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsMicroRNAshematological malignanciesleukemialymphomamicroRNAstatin

Identifiers

PMID39766267
PMCPMC11673652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.